Literature DB >> 31248676

The Association of the Average Epinephrine Dosing Interval and Survival With Favorable Neurologic Status at Hospital Discharge in Out-of-Hospital Cardiac Arrest.

Brian Grunau1, Takahisa Kawano2, Frank X Scheuermeyer3, Ian Drennan4, Christopher B Fordyce5, Sean van Diepen6, Joshua Reynolds7, Steve Lin8, Jim Christenson3.   

Abstract

STUDY
OBJECTIVE: For patients with out-of-hospital cardiac arrest, the recommended dosing interval of epinephrine is 3 to 5 minutes, but this recommendation is based on expert opinion without data to guide optimal management. We seek to evaluate the association between the average epinephrine dosing interval and patient outcomes.
METHODS: In a secondary analysis of the Resuscitation Outcomes Consortium continuous chest compression trial, we identified consecutive patients treated with greater than or equal to 2 doses of epinephrine. We defined average epinephrine dosing interval as resuscitation duration after the first dose of epinephrine divided by the total administered epinephrine, and categorized the dosing interval in minutes as less than 3, 3 to less than 4, 4 to less than 5, and greater than or equal to 5. We fit a logistic regression model to estimate the association of the average epinephrine dosing interval category with survival with favorable neurologic status (modified Rankin Scale score ≤3) at hospital discharge.
RESULTS: We included 15,909 patients (median age 68 years [interquartile range 56 to 80 years], 35% women, 13% public location, 46% bystander cardiopulmonary resuscitation, and 19% initial shockable rhythm). The median epinephrine dosing interval was 4.3 minutes (interquartile range 3.5 to 5.3 minutes). Survival with favorable neurologic status occurred in 4.7% of patients. Compared with the reference dosing interval of less than 3 minutes, longer epinephrine dosing intervals were associated with lower survival with favorable neurologic status: dosing interval 3 to less than 4 minutes, adjusted odds ratio 0.44 (95% confidence interval 0.32 to 0.60); 4 to less than 5 minutes, adjusted odds ratio 0.26 (95% confidence interval 0.18 to 0.36); and greater than or equal to 5 minutes, adjusted odds ratio 0.21 (95% confidence interval 0.15 to 0.30).
CONCLUSION: In this out-of-hospital cardiac arrest series, a shorter average epinephrine dosing interval was associated with improved survival with favorable neurologic status.
Copyright © 2019 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31248676     DOI: 10.1016/j.annemergmed.2019.04.031

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  4 in total

1.  Pediatric cardiopulmonary resuscitation quality during intra-hospital transport.

Authors:  Morgann Loaec; Adam S Himebauch; Todd J Kilbaugh; Robert A Berg; Kathryn Graham; Richard Hanna; Heather A Wolfe; Robert M Sutton; Ryan W Morgan
Journal:  Resuscitation       Date:  2020-05-15       Impact factor: 5.262

2.  Urban-Rural Differences in Cardiac Arrest Outcomes: A Retrospective Population-Based Cohort Study.

Authors:  Michael S Connolly; Judah P Goldstein Pcp; Margaret Currie; Alix J E Carter; Steve P Doucette; Karen Giddens; Katherine S Allan; Andrew H Travers; Beau Ahrens; Daniel Rainham; John L Sapp
Journal:  CJC Open       Date:  2021-12-30

Review 3.  Pediatric In-Hospital Cardiac Arrest and Cardiopulmonary Resuscitation in the United States: A Review.

Authors:  Ryan W Morgan; Matthew P Kirschen; Todd J Kilbaugh; Robert M Sutton; Alexis A Topjian
Journal:  JAMA Pediatr       Date:  2021-03-01       Impact factor: 16.193

4.  The Effect of Epinephrine Dosing Intervals on Outcomes from Pediatric In-Hospital Cardiac Arrest.

Authors:  Martha F Kienzle; Ryan W Morgan; Jennifer A Faerber; Kathryn Graham; Hannah Katcoff; William P Landis; Alexis A Topjian; Todd J Kilbaugh; Vinay M Nadkarni; Robert A Berg; Robert M Sutton
Journal:  Am J Respir Crit Care Med       Date:  2021-10-15       Impact factor: 30.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.